Biotech_Tradez
5 days ago
I called you out for being a Paid Cheerleader and you denied it, while having received 3,500,000 shares of stock.
I also called you out for spreading lies and misinforming people about this contraption. Among the lies is that the device works and is "FDA Approved." This device is FDA Cleared not Approved and in recent studies it, specifically the Rhodes study, was basically the same as a placebo.
This device has not been shown to be effective in large human studies and was cleared by the FDA based on a resubmitted 510(k) arguing that the device was "substantial equivalent" to a device that was already legally marketed before the FDA started regulating medical devices.
You are either ignorant and severely misinformed or you are spreading lies. I have on numerous occasions stated that this device is not FDA Approved yet you keep spreading the lie that it is despite the evidence to the contrary. If the contraption were FDA approved then it would have the clinical trials to show its effectiveness and it would have sales.
The main difference between FDA clearance and FDA approval is the level of regulatory scrutiny and the types of evidence required:
FDA approval
A higher standard that involves extensive research, clinical trials, and documentation of safety, efficacy, and manufacturing processes. The FDA decides that the benefits of the product outweigh the known risks.
FDA clearance
A lower standard that involves demonstrating that the product is "substantially equivalent" to another similar legally marketed device that has already been approved. Specific testing on FDA cleared products may be absent or minimal.
The FDA uses two distinct regulatory procedures for approval and clearance:
FDA-approved
Manufacturers must submit a Premarket Approval (PMA) application that contains results from clinical investigations.
FDA-cleared
Manufacturers can submit a Premarket Notification (also called a 510(k)) to the FDA.
Biotech_Tradez
5 days ago
Funny that the account you use to post your "opinions" is also the name of the company that was paid 3,500,000 shares.
Your own words on January 13, 2023 Post # 32689:
With so much coming from the company the bears are in full scramble mode to bash this ticker now. Since they canβt say the product doesnβt work and the new management coming on in Mr Kann and Ira are both highly respected in their fields itβs seems important to build a false rhetoric around what caused the previous launch to fail so they can hold this down longer.
Itβs in the best interest of all past and future shareholders as well as the community at larger to support the relaunch of this product, get it to the people who it can HELP and return value to shareholders.
Thank you
Giving investment advice while taking shares from the company without disclosing that fact is likely illegal. You are either brazen, dumb or have a really bad attorney.
Biotech_Tradez
5 days ago
No, Jeff Lien, aka PennyStockSnipers, aka Cornerstone Marketing is a penny stock promoter that shows up on penny stock boards, Discord and other platforms to pump stocks he is compensated for without disclosing that fact.
You showed up here in December of 2022 as PennyStockSnipers to pump this stock when it was trading sub penny and had very little volume. You not only probably bought shares sub penny before you started pumping the stock, but you also received 3,500,000 shares of common stock on 1/03/23. Convenient how you didn't mention that fact in your little DD package. In fact you outright denied it numerous times when you were called out for it. You can call yourself whatever you want but the truth is you pumped this stock.
Your own words on December 14, 2022 - Post # 32627
Funny how the bears run away as this continues to shine. Company is starting to slowly come out of a forced closure due to the pandemic. Letβs see what they have plannedβ¦ I bet itβs HUGE based on what weβve seen so far. Headed back to NASDAQ
Does that sound like social media management to anyone, or more like pumping a stock? When the pumpers call you a bear it is a clear sign they have no argument at all. Not only did everything I said come true including calling you out when you first showed up as a penny stock pumper, but this company did not go "back to NASDAQ" because it never was on it, it went even further down losing people 90% or more of their investment, none of their sales plans panned out and they were delisted from the OTCQB down to the pink sheets and based on their quarterly report, they generated $0 sales last quarter.
Do everyone a favor and leave, permanently this time. I would not be surprised if the SEC comes knocking at your door or a lawsuit comes your way given your cavalier attitude and brazen stock promotion.
Biotech_Tradez
6 days ago
BUYER BEWARE: Jeff Lien aka Cornerstone Marketing is a paid stock promoter that doesn't disclose he is getting paid by the companies he is promoting.
ENDV granted Jeff Lien of Cornerstone Marketing, aka PennyStockSnipers, 3,500,000 shares of common stock on 1/03/23 just before he magically appeared on this and other penny stock boards promoting the stock. A fact that Jeff Lien never disclosed when promoting the stock, which may be illegal. Anyone that bought on the advice of Jeff Lien, aka Cornerstone Marketing, aka PennyStockSnipers and lost money should look to sue him and report him to the SEC.
Craig Please post this as a sticky. Potential investors must be aware of who this person is and what his motivation is behind pushing this stock.
Biotech_Tradez
2 weeks ago
BUYER BEWARE: New ENDV Target Stock Price is $0.0004 See Below:
On June 11, 2024 ENDV issued 19,807,975 shares of common stock at a price of $0.0004 to Trillium Partners, LP for the conversion of $7,923 in debt. The closing stock price on 6/11/24 was $0.0008 per share, thus the conversion was at a 50% discount to the closing price.
This conversion was preceded by the issuance of 25,875,613 shares of common stock at a price of $0.0008 to Trillium Partners, LP for the conversion of $20,700 in debt. The conversion was done on 5/15/24 when the closing price of the common stock was $0.0016 per share, thus the conversion was at a 50% discount to the closing price. Since that conversion the price has been driven down 50% to the price of the conversion at $0.0008 per share.
Therefore the volume that has been generated has been through the selling of the highly discounted conversion shares into the market. This means that the stock price will be driven down as long as they can get $0.0004 per share. An informed investor would thus not buy below the conversion price since there is a shareholder with a lower cost basis that is motivated to sell shares.
These conversions are being outlined in the quarterly reports submitted to the SEC. The good thing about these idiots being delisted from the OTCQB down to the pink sheets is that they now have to disclose their stock issuances, broken down in detail including the date, number of shares, the name of the person being issued shares and the price at which the shares are issued.
This has not only revealed the conversion of debt at steep discounts but also highlighted that Alan Collier, the CEO and sole Board Member has gifted himself over 45 million shares via his consulting firm Blue Ridge Consulting. This is of course a reward for diluting all of his investors following a 1-for-1,000 reverse split followed by the issuance of over 350,000,000 shares resulting in investors losing over 99.99% of their investments. So while his investors were completely wiped out, Alan Collier increased his ownership stake in ENDV.
Furthermore, upon a more detailed review, the quarterly report also states that ENDV granted Jeff Lien of Cornerstone Marketing, aka PennyStockSnipers, 3,500,000 shares of common stock on 1/03/23 just before he magically appeared on this and other penny stock boards promoting the stock. A fact that Jeff Lien never disclosed when promoting the stock, which may be illegal. Anyone that bought on the advice of Jeff Lien, aka Cornerstone Marketing, aka PennyStockSnipers and lost money should look to sue him and report him to the SEC.
Craig, please highlight this post as a sticky, it is too important for potential new investors to be informed of what they are getting themselves into. If they read this and decide to still buy then that is on them, after all these penny stocks are Caveat Emptor.
Biotech_Tradez
2 weeks ago
They had ZERO revenue in Q3 and Negative $330 in Cash.
The numbers are for the nine months ending September 30. If you compare the numbers from the last report they are the same for both revenue and COGS.
Period ending 6/30 Revenue: $10,043 and COGS: $6,709 Gross Profit: $3,335
Period ending 9/30 Revenue: $10,043 and COGS: $6,709 Gross Profit: $3,335 EXACTLY THE SAME NUMBERS WHIICH MEANS NO REVENUE! They did not sell a single contraption in the last 3 months.
ENDV has virtually no assets and nearly $20 million in very real liabilities. Furthermore, their contraption has not been shown to be effective in large double-blind randomized and controlled clinical trials necessary to receive reimbursement and/or justify the cost in surgery.
It has been two years since they announced their proposed spin off yet no real progress has been made. My guess is that their new guy Ira cannot get the financing to take this POS into a NASDAQ company. This company's only avenue is bankruptcy court to rid itself or fundamentally restructure its debt. The company cannot repay $7 million in debt along with another $5.6 million in accrued interest no matter what financing scheme they purport to have brewed up. It is difficult to see what value they got for $7 million in debt they put on the company besides Collier paying himself and his cronies bloated salaries. You could build a very successful company with that amount and yet these idiots have only every driven down the value of the company and its assets.
Craig305
2 months ago
UNITED STATES OF AMERICA
BEFORE THE
SECURITIES AND EXCHANGE COMMISSION
September 19, 2024
__________________________________
In the Matter of
Endonovo Therapeutics, Inc. 6320 Canoga Avenue, 15th Floor Woodland Hills, CA 91367
ORDER DECLARING OFFERING STATEMENT ABANDONED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
File No: 024-11805
__________________________________
Endonovo Therapeutics, Inc. filed with the Commission an offering statement to qualify an offering of securities under Section 3(b) of the Securities Act of 1933. The offering statement has been on file for more than nine months and has not yet been qualified.
In view of the foregoing, it is ORDERED that the offering statement be declared abandoned on September 19, 2024.
For the Commission, by the Division of Corporation Finance, pursuant to delegated authority.
Craig305
5 months ago
Held at DTC Shares Updated:
🔴 176,772,058 (2024-05-24)
🟢 196,580,033 (2024-06-14)
Difference: +11.2% (+19M)
Outstanding Shares Updated:
🔴 377,019,970 (2024-05-24)
🟢 396,827,945 (2024-06-14)
Difference: +5.3% (+19M)
Unrestricted Shares Updated:
🔴 181,726,791 (2024-05-24)
🟢 201,534,766 (2024-06-14)
Difference: +10.9% (+19M)
Craig305
6 months ago
$ENDV
💰0.0013
Pink Current, AS: 2.5B, OS: 377M, US: 181M
Held at DTC Shares Updated:
🔴 150,896,445 (2024-05-03)
🟢 176,772,058 (2024-05-24)
Difference: +17.1% (+25M)
Outstanding Shares Updated:
🔴 349,394,357 (2024-05-03)
🟢 377,019,970 (2024-05-24)
Difference: +7.9% (+27M)
Restricted Shares Updated:
🔴 193,543,179 (2024-05-03)
🟢 195,293,179 (2024-05-24)
Difference: +0.9% (+1.8M)
Unrestricted Shares Updated:
🔴 155,851,178 (2024-05-03)
🟢 181,726,791 (2024-05-24)
Difference: +16.6% (+25M)
Chart, OTC Profile, Twitter, @otcupdates